The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
"Dopamine System Stabilizers, Aripiprazole, and the Next Generation of Antipsychotics, Part 1: "Goldilocks" Actions at Dopamine Receptors: (Brainstorms)
Open accessAbstract
Article AbstractBrainstorms: Psychosis occurs when too much dopamine exists in the synapses, and the action, akin to Goldilocks's first bowl of soup, is "too hot." Every antipsychotic that reduces the positive symptoms of psychosis such as delusions and hallucinations does so by blocking dopamine D2 receptors, most likely those of the mesolimbic dopamine pathway. Unfortunately, the blocking is often nonspecific, which is typical of conventional antipsychotic actions. Thus, when D2 receptors in the nigrostriatal dopamine pathway are also blocked, a penalty is paid in motor side effects, namely extrapyramidal reactions, pseudoparkinsonism, and ultimately, tardive dyskinesia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Finally, third-generation antipsychotics, such as aripiprizole, are partial D2 receptor agonists with high affinity and low intrinsic activity, and these drugs may act as ‘DA stabilizers’ because of their ability to stabilize, rather than simply upregulate or downregulate functional output of DA systems [428].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vliet, B. J. V., Ronken, E., Tulp, M. T. M., Feenstra, R., Kruse, C. G., & Long, S. K. (2000) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(00)80319-3 · Cited by 12
Research works printed but not linked: 6
- Stahl SM. Essential Psychopharma- cology. 2nd ed. New York, NY: Cambridge University Press; 2000
- Carlsson A, Waters N, Carlson ML. Biol Psychiatry 1999;46:1388-1395
- Toru M, Miura S, Kudo Y. Neuro- psychopharmacology 1994;10:122S
- Lawler CP, Prioleau C, Lewis MM, et al. Neuropsychopharmacology 1999; 20:612-627
- Ekesbo A, Andren PE, Gunne LM, et al. NeuroReport 1997;8:2567-2570
- Lahti AC, Weiler MA, Corey PK, et al. Biol Psychiatry 1998;43:2-11 The author gratefully acknowledges the review of this feature by Herbert Y. Meltzer, M.D.; Terrance H. Andree, Ph.D.; and Robert McQuaid, Ph.D.
Cited by
Sorted by citations
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B. K., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,131
Bilder, R. M., Volavka, J., Lachman, H. M., & Grace, A. A. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300542 · Cited by 769
Keck, P. E., Marcus, R. N., Tourkodimitris, S., Ali, M. W., Liebeskind, A., Saha, A. R., Ingenito, G. G., & Aripiprazole Study Group (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.9.1651 · Cited by 501
Marder, S. R., McQuade, R. D., Stock, E. G., Kaplita, S., Marcus, R. N., Safferman, A. Z., Saha, A. R., Ali, M. W., & Iwamoto, T. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(03)00050-1 · Cited by 467
Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability
DeLeon, A., Patel, N. C., & Crismon, M. L. (2004) · Clinical Therapeutics · doi:10.1016/s0149-2918(04)90066-5 · Cited by 364
Metadata
- Authors
- Stahl, S. M.
- Affiliations
- Neuroscience Education Institute (US)
- Corresponding author
- Stahl, Stephen M.
- ORCID
- Stahl, Stephen M.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-11-15
- Volume
- 62
- Issue
- 11
- Pages
- 841-842
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2091915431
- Cited by
- 143
- References
- 1
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 2 · 2023: 6 · 2022: 8 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 2 · 2014: 6 · 2013: 3 · 2012: 10
- FWCI
- 5.12
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- aripiprazole, dopamine D2 receptor, dopamine agonists, antipsychotic drugs, psychosis, mesolimbic dopamine system, nigrostriatal dopamine pathway, extrapyramidal symptoms, tardive dyskinesia, positive symptoms
- MeSH terms
- Aripiprazole, Binding Sites, Corpus Striatum, Humans, Piperazines, Psychotic Disorders, Substantia Nigra, Antipsychotic Agents, Dopamine Agents, Quinolones, Receptors, Dopamine D2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
